Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:7/31/2014)... Texas (PRWEB) August 01, 2014 ... and China Polyurethane Resin Industry” is a ... Resin market. The report introduces Polyurethane Resin ... and industry chain structure and industry overview. ... including China’s domestic market as well as ...
(Date:7/31/2014)... and even the entire body to visualize long-range connections ... been a long-time dream of biologists. A study published ... journal Cell has now made that dream ... bodies, and human tissue biopsies transparent, while keeping the ... the way for a better understanding of brain-body interactions, ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving ... said today that it believes the executive order signed ... of stem cell research is a significant move forward ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the Cowen and Company 29th Annual Health Care Conference ... p.m. ET. About Cynvec LLC , ...
... March 9 Merrimack Pharmaceuticals, Inc., a privately held ... novel treatments for cancer and autoimmune disease, today announced ... Vice President and Chief Scientific Officer and Edward (Tad) ... "Ulrik and Tad have both played critical roles ...
Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
(Date:8/1/2014)... two Simon Fraser University research associates, cite new ... collaborate closely on minimizing damage to the natural ... Maureen Ryan, David H. Smith Conservation Research Fellows ... international co-authors of the newly published research in ... , Shale gas development is the extraction of ...
(Date:7/31/2014)... prestin was found to be a key gene responsible for ... the hair cells of the inner ear that contracts and ... an antique phonograph horn, amplify sound waves to make hearing ... in the advanced online edition of Molecular Biology and ... has also independently evolved to play a critical role in ...
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Certain Arctic lakes store more greenhouse gases than they release 2
... HOBOKEN, N.J. (June 23, 2010) An estimated 60 ... commonly known as hay fever, according to the American Academy ... allergic inflammation of the nasal airways that causes itching, swelling, ... the June 14, 2010 issue of Phytotherapy Research ...
... scientists from the University of Nevada, Reno, DRI, Arizona ... from a two-week expedition to Guatemala,s tropical high-mountain Lake ... the algae blooms that have assailed the ecosystem and ... lake,s water is contaminated with watershed runoff and waste ...
... In what is believed to be the largest review of the ... more likely to clump faster than others, scientists at Johns Hopkins ... they say likely control that bodily function. "Our results give ... from these genes, to develop tests that could help us identify ...
Cached Biology News:Study demonstrates pine bark naturally reduces hay fever symptoms 2Study demonstrates pine bark naturally reduces hay fever symptoms 3American team of scientists help protect Guatemala's Lake Atitlan 2American team of scientists help protect Guatemala's Lake Atitlan 3Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3
...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
Biology Products: